Anjali Jacob is a Respiratory physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
505 Parnassus Ave
San Francisco, CA 941432204
Telephone
415-476-1000Provider last certified this registry record 21 Oct 2024.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
67%Leukotriene Receptor Antagonist27%Montelukast Sodium100%Part D<11 patientsbeta2-Adrenergic Agonist23%Albuterol Sulfate Hfa100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
22%Pyridone22%Pirfenidone100%Part D<11 patientsAnti-infectives
11%Macrolide Antimicrobial11%Azithromycin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2024–2026 per NIH RePORTER. The latest:
- Modulating signaling pathways in the fibrotic lung using synthetic biology tools
University of California, San Francisco
FY2026$174,744K08HL186457 - Modulating signaling pathways in alveolar epithelial cells with engineered T cells
University of California, San Francisco
FY2025$82,744F32HL172536 - Modulating signaling pathways in alveolar epithelial cells with engineered T cells
University of California, San Francisco
FY2024$78,892F32HL172536
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”